Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05004688 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD
A Phase 2 study of Alzheimer Disease and Mild Cognitive Impairment, sponsored by Steven E Arnold, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05004688 is a Phase 2 study of Alzheimer Disease and Mild Cognitive Impairment that has completed, run by Steven E Arnold, MD. The registered enrollment target is 15 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05004688, a Phase 2 study of Alzheimer Disease and Mild Cognitive Impairment, has completed, sponsored by Steven E Arnold, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
A study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older with mild cognitive impairment and mild-to-moderate to Alzheimer's disease.
Conditions Studied
Interventions
- BIOLOGICAL Biological/Vaccine: Bacillus Calmette-Guerin (BCG)
Study Locations (1)
Massachusetts
- Alzheimer's Clinical and Translational Research Unit - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-03-25 |
| Est. Completion | 2024-01-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05004688
The ClinicalTrials.gov registry entry for NCT05004688 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (99% lower). The listed sponsor is Steven E Arnold, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Biological/Vaccine: Bacillus Calmette-Guerin (BCG) is the first listed.
NCT05004688 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05004688 about?
NCT05004688 is a clinical study titled "A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD". A study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older with mild cognitive impairment and mild-to-moderate to Alzheimer's disease.
What is the current status of trial NCT05004688?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2022-03-25. Estimated completion is 2024-01-15.
What conditions does trial NCT05004688 study?
This clinical trial studies the following conditions: Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Moderate Dementia.
What interventions are being tested in trial NCT05004688?
The interventions under investigation include: Biological/Vaccine: Bacillus Calmette-Guerin (BCG) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05004688?
This trial is sponsored by Steven E Arnold, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05004688 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
RECRUITING · Phase 2
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RECRUITING · Phase 2
-
Sleep Trial to Prevent Alzheimer's Disease
RECRUITING · Phase 2
-
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
RECRUITING · Phase 2
-
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.